Rosuvastatin Dosing with Bempedoic Acid
When combining bempedoic acid with rosuvastatin, use standard rosuvastatin doses without restriction, as the drug interaction is minimal and does not require dose adjustment.
Key Evidence from FDA Drug Label
The FDA label for bempedoic acid specifically evaluated the pharmacokinetic interaction with rosuvastatin 10 mg and found only a 1.7-fold elevation in AUC of rosuvastatin and its metabolites 1. Critically, the label states these elevations "were generally within the individual statin exposures and do not impact dosing recommendations" 1.
Practical Dosing Approach
For Patients at Very High Risk (Post-ACS, Established ASCVD)
- Start with rosuvastatin 40 mg + bempedoic acid 180 mg (with or without ezetimibe 10 mg) as upfront combination therapy 2
- This triple combination (rosuvastatin 40 mg + ezetimibe 10 mg + bempedoic acid 180 mg) achieved:
- 57.7% LDL-C reduction at 1 week
- 76.3% of patients reaching <50 mg/dL target within 2 weeks 2
For Patients at High Risk
- Rosuvastatin 20 mg + bempedoic acid 180 mg is appropriate as initial combination therapy 3
- Consider adding ezetimibe if LDL-C goals not met at 4-6 weeks
Important Contrast: Simvastatin and Pravastatin Restrictions
Unlike rosuvastatin, bempedoic acid has clinically significant interactions with:
- Simvastatin: Avoid doses >20 mg daily (2-fold AUC increase) 4, 1
- Pravastatin: Avoid doses >40 mg daily (2-fold AUC increase) 4, 1
These restrictions exist because bempedoic acid inhibits OATP1B1 and OATP1B3 transporters, which are critical for hepatic uptake of simvastatin and pravastatin but less so for rosuvastatin 1.
Clinical Monitoring
- No special dose adjustments needed for rosuvastatin when combined with bempedoic acid
- Monitor for hyperuricemia and tendon-related symptoms (bempedoic acid warnings) 4
- Check LDL-C at 4-6 weeks to assess goal attainment 4
The 1.7-fold increase in rosuvastatin exposure with bempedoic acid is not clinically meaningful and falls within the normal variability of statin pharmacokinetics, making rosuvastatin one of the preferred statins for combination with bempedoic acid 1.